Advertisement

Wrapping-Based Re-engineering of an Anticancer Drug to Make it Safer

  • Ariel Fernández Stigliano
Chapter

Abstract

As indicated in the previous chapter, molecular therapeutic approaches to cancer are often geared at interfering with signaling pathways that govern cell fate or proliferation. These strategies target kinases, the signal transducers in the cell. This approach remains challenging because kinases are evolutionarily and therefore structurally related and thus kinase inhibitors (KIs) often lack the required specificity, which may lead to toxic side effects. This chapter illustrates the power of the wrapping concept in engineering safer KIs, thus unraveling a rational approach to fulfill this therapeutic imperative. The focus of this chapter is the redesign of the anticancer drug imatinib (Gleevec) used to treat chronic myeloid leukemia, where its primary target is the chimeric Bcr-Abl kinase, as well as certain solid tumors based on its impact on the C-Kit kinase. Imatinib also has potentially cardiotoxic effects traceable to its impact on the Abl kinase in off-target cells. This chapter describes a wrapping modification of imatinib purposely designed to prevent inhibitory impact against Abl (and Bcr-Abl), to refocus the impact toward C-Kit and to promote inhibition of an additional target, JNK, required to reinforce the prevention of cardiotoxicity and recognized as a target of significant therapeutic interest in its own right. The molecular blueprint for target discrimination, described in Chaps. 4 and 6, is now validated through assays that span a vast testing ground, from in silico assessment and test tube probes to animal models. The findings surveyed in this chapter identify the wrapping-based re-engineered imatinib as an agent to treat gastrointestinal stromal tumors and possibly ovarian cancer (via its differential anti-JNK activity) with reduced side effects, thereby illustrating the therapeutic impact of the wrapping technology.

Keywords

Chronic Myeloid Leukemia Brain Natriuretic Peptide Stem Cell Factor Pancreatic Ductal Adenocarcinoma Inhibitory Impact 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Dancey J, Sausville EA (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296–313CrossRefPubMedGoogle Scholar
  2. 2.
    Levitski A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267:1782–1788CrossRefGoogle Scholar
  3. 3.
    Tibes R, Trent J, Kurzrock R (2005) Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharm Tox 45:357–384CrossRefGoogle Scholar
  4. 4.
    Gibbs J, Oliff A (1994) Pharmaceutical research in molecular oncology. Cell 79:193–198CrossRefPubMedGoogle Scholar
  5. 5.
    Donato NJ, Talpaz M (2000) Clinical use of tyrosine kinase inhibitors: therapy for chronic myelogenous leukemia and other cancers. Clin Cancer Res 6:2965–2966PubMedGoogle Scholar
  6. 6.
    Fabian MA, Biggs WH, Treiber DK et al (2005) A small molecule kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329–336CrossRefPubMedGoogle Scholar
  7. 7.
    Gambacorti-Passerini C, le Coutre P, Mologni L et al (1997) Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL + leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380–394CrossRefPubMedGoogle Scholar
  8. 8.
    Schindler T, Bornmann W, Pellicena P et al (2000) Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942CrossRefPubMedGoogle Scholar
  9. 9.
    Attoub S, Rivat C, Rodrigues S et al (2002) The c-kit tyrosine kinase inhibitor STI-571 for colorectal cancer therapy. Cancer Res 62:4879–4883PubMedGoogle Scholar
  10. 10.
    DeMatteo RP (2002) The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 9:831–839CrossRefPubMedGoogle Scholar
  11. 11.
    Skene RJ, Kraus ML, Scheibe DN et al (2004) Structural basis for autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J Biol Chem 279:31655–31663CrossRefPubMedGoogle Scholar
  12. 12.
    Tuveson DA, Willis NA, Jacks T et al (2001) STI571 inactivation of the gastrointestinal stromal tumor c-kit oncoprotein: biological and clinical implications. Oncogene 20:5054–5058CrossRefPubMedGoogle Scholar
  13. 13.
    Chen JP, Zhang X, Fernández A (2007) Molecular basis for specificity in the druggable kinome: sequence-based analysis. Bioinformatics 23:563–572CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Fernández A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, Wulf S, Shavrin A, Qin C, Ma J, Trent J, Lin Y, Han HD, Mangala LS, Bankson JA, Gelovani J, Samarel A, Bornmann W, Sood AK, Lopez-Berestein G (2007) An anticancer c-kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 117:4044–4054CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Kerkela R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916CrossRefPubMedGoogle Scholar
  16. 16.
    Druker BJ (2004) Molecularly targeted therapy: have the floodgates opened? Oncologist 9:357–360CrossRefPubMedGoogle Scholar
  17. 17.
    Vivas-Mejia P, Benito JM, Fernández A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G (2010) c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16:184–194CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Fernández A, Scheraga HA (2003) Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc Natl Acad Sci USA 100:113–118CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Barker S, Kassel D, Weigl D et al (1995) Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 34:14843–14851CrossRefPubMedGoogle Scholar
  20. 20.
    Songyang Z, Carraway KL, Eck M et al (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536–539CrossRefPubMedGoogle Scholar
  21. 21.
    Clarkson B, Strife A, Wisniewski D, Lambek CL, Liu C (2003) Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategy. Leukemia 17:1211–1262CrossRefPubMedGoogle Scholar
  22. 22.
    Baines CP, Molkentin JD (2005) Stress signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38:47–62CrossRefPubMedGoogle Scholar
  23. 23.
    Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to Imatinib by small animal positron emission tomography. Anticancer Res 26:1247–1252PubMedGoogle Scholar
  24. 24.
    Scheuermann-Freestone M, Simon Freestone N, Langenickel T et al (2001) A new model of congestive heart failure in the mouse due to chronic volume overload. Eur J Heart Fail 3:535–543CrossRefPubMedGoogle Scholar
  25. 25.
    Theoharides T (2008) Mast cells and pancreatic cancer. N Engl J Med 358:1860–1861CrossRefPubMedGoogle Scholar
  26. 26.
    Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Unkeless J, Xiong H, Feng ZH (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112:1269–1279CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hemat 77:12–19CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.National Research Council–CONICETBuenos AiresArgentina
  2. 2.Former Karl F. Hasselmann Endowed Chair Professor of BioengineeringRice UniversityHoustonUSA

Personalised recommendations